Dexcom to appoint two directors, revamp board committee with Elliott

Dexcom to add 2 board directors with activist investor Elliott

CEO Jake Leach also discussed the company’s plans for its G8 glucose sensor, dual-analyte sensing and Medicare coverage at an investor day.

Dexcom to appoint two directors, revamp board committee with Elliott

By Siddhi Mahatole May 14 (Reuters) – Medical device maker Dexcom said on Thursday it will appoint two independent directors and revamp a key board committee ​in collaboration with activist investor Elliott Investment Management. Shares ‌of Dexcom were up about 6% in after-hours trading. Dexcom CEO Jake Leach said on an investor call that the company is focusing on refreshing its board and seeks to add independent ‌directors ​with medtech and op…